Dr. Bolognani joins Axial Therapeutics with over 20 years of experience in translational neuroscience research in academia, pharmaceutical and the biotechnology industries. Most recently, Federico served as the Vice President and Head of Clinical Science at VectivBio in Basel, Switzerland. Prior to VectivBio AG, Dr. Bolognani was VP and Head of Clinical Science at Therachon AG, which was acquired by Pfizer in 2019. Prior to Therachon, Dr. Bolognani held various senior-level positions at Roche. As Translation Medicine Leader, Dr. Bolognani led several of Roche’s programs in neuroscience, including the successful Phase 2 Balovaptan program in ASD, which was granted Breakthrough Designation in 2018. Dr. Bolognani received his Ph.D. and M.D. from Universidad Nacional de La Pata, Argentina and has an extensive scientific publication record in translational neuroscience research.